Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO ‐ PROFIT study

Documenti analoghi

• Impact of level 2 hypoglycaemia on neuroaxonal damage biomarker in individuals with type 2 diabetes: A stepwise hypoglycaemic clamp study
  di: Harald Sourij, et al.
  Pubblicazione: (2025)
• Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design
  di: Caren Sourij, et al.
  Pubblicazione: (2026)
• Impact of intermittent fasting on self‐regulatory behaviour and sleep in participants with insulin‐treated type 2 diabetes: A secondary analysis of the INTERFAST‐2 randomised controlled trial
  di: Anna Ramirez‐Obermayer, et al.
  Pubblicazione: (2026)
• Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial
  di: Caren Sourij, et al.
  Pubblicazione: (2024)
• Acute and prolonged effects of aerobic endurance training on N‐lactoyl‐phenylalanine and inflammatory markers in individuals with type 1 diabetes: An exploratory analysis of the ULTRAFLEXI ‐1 study
  di: Ulrike Glatz, et al.
  Pubblicazione: (2025)